Candel Therapeutics, Inc. (CADL) stock
CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.32−0.08 (-1.48%)
Close on Nov 18, 2026Market cap $407.08MP/E –Yield –
Candel Therapeutics cash
Cash and short-term investments held at the end of each period.
Candel Therapeutics's cash was $201.57M at Jun 30, 2026. For fiscal 2025 it was $119.73M, up 16.3% from the year before. The highest annual figure on record is $119.73M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.73M | +16.3% |
| FY2024 | Dec 31, 2024 | $102.92M | +188.5% |
| FY2023 | Dec 31, 2023 | $35.68M | -49.3% |
| FY2022 | Dec 31, 2022 | $70.32M | -15.3% |
| FY2021 | Dec 31, 2021 | $83.07M | +135.2% |
| FY2020 | Dec 31, 2020 | $35.32M | +548.7% |
| FY2019 | Dec 31, 2019 | $5.45M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $201.57M | +99.7% |
| Q1 FY2026 | Mar 31, 2026 | $194.83M | +110.8% |
| Q4 FY2025 | Dec 31, 2025 | $119.73M | +16.3% |
| Q3 FY2025 | Sep 30, 2025 | $86.96M | +416.9% |
| Q2 FY2025 | Jun 30, 2025 | $100.95M | +364.8% |
| Q1 FY2025 | Mar 31, 2025 | $92.43M | +255.8% |
| Q4 FY2024 | Dec 31, 2024 | $102.92M | +188.5% |
| Q3 FY2024 | Sep 30, 2024 | $16.82M | -61.1% |
| Q2 FY2024 | Jun 30, 2024 | $21.72M | -58.4% |
| Q1 FY2024 | Mar 31, 2024 | $25.98M | -56.4% |
| Q4 FY2023 | Dec 31, 2023 | $35.68M | -49.3% |
| Q3 FY2023 | Sep 30, 2023 | $43.25M | -44.2% |
| Q2 FY2023 | Jun 30, 2023 | $52.16M | -40.1% |
| Q1 FY2023 | Mar 31, 2023 | $59.52M | -37.2% |
| Q4 FY2022 | Dec 31, 2022 | $70.32M | -15.3% |
| Q3 FY2022 | Sep 30, 2022 | $77.45M | -12.8% |
| Q2 FY2022 | Jun 30, 2022 | $87.05M | +251.9% |
| Q1 FY2022 | Mar 31, 2022 | $94.76M | +220.4% |
| Q4 FY2021 | Dec 31, 2021 | $83.07M | +135.2% |
| Q3 FY2021 | Sep 30, 2021 | $88.81M | +379.4% |
| Q2 FY2021 | Jun 30, 2021 | $24.74M | +19.2% |
| Q1 FY2021 | Mar 31, 2021 | $29.58M | +443.2% |
| Q4 FY2020 | Dec 31, 2020 | $35.32M | – |
| Q3 FY2020 | Sep 30, 2020 | $18.52M | – |
| Q2 FY2020 | Jun 30, 2020 | $20.76M | – |
| Q4 FY2019 | Dec 31, 2019 | $5.45M | – |
See a number that looks wrong?